The following Structured Product Label (SPL) was submitted to the FDA by Oyster Point Pharma, Inc. for the product Ryzumvi (NDC 83368-075). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 treatment of presbyopia, 2.2 treatment of pharmacologically-induced mydriasis, 2.3 administration instructions, 3 dosage forms and strengths, 4 contraindications, 5.1 uveitis, 5.2 potential for eye injury or contamination, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
RYZUMVI is indicated for:
Adults: Instill 1 drop in both eyes once daily at night.
Adults and Pediatric Patients Aged 12 Years or Older: Instill 1 or 2 drops in each dilated eye following the completion of the ophthalmic examination or procedure. If 2 drops are instilled, the second drop should be administered 5 minutes after the first drop.
Pediatric Patients Aged 3 to 11 Years: Instill 1 drop in each dilated eye following the completion of the ophthalmic examination or procedure.
Remove contact lenses prior to the instillation of RYZUMVI. Contact lenses may be reinserted 10 minutes after instillation.
If more than one topical ophthalmic product is being used, the products should be administered at least 5 minutes apart.
To open vial, twist off top (see Figure 1).
Dosage And Administration Twist Top Figure (Image 02)
One single-dose vial may be used to dose both eyes. Discard the single-dose vial immediately after use.
Ophthalmic solution: clear and colorless solution containing phentolamine 0.75% in a single-dose vial.
None.
RYZUMVI is not recommended when active ocular inflammation (e.g., iritis) is present because adhesions (synechiae) may form between the iris and the lens.
To avoid the potential for eye injury or contamination, care should be taken to avoid touching the vial tip to the eye or to any other surface.
Contact lens wearers should be advised to remove their lenses prior to the instillation of RYZUMVI and wait 10 minutes after dosing before reinserting their contact lenses.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
RYZUMVI was evaluated in 534 subjects in clinical trials for the treatment of presbyopia. The most common ocular adverse reactions reported in > 5% of subjects were conjunctival hyperemia (21%) and instillation site irritation (16%).
RYZUMVI was evaluated in 642 subjects in clinical trials for the treatment of pharmacologically-induced mydriasis. The most common ocular adverse reactions reported in > 5% of subjects were instillation site discomfort including pain, stinging, and burning (16%) and conjunctival hyperemia (12%). The only non-ocular adverse reaction reported in > 5% of subjects was dysgeusia (6%). The majority of the adverse reactions were mild, transient and self-resolving.
There are no available data with RYZUMVI administration in pregnant women to inform a drug-associated risk. In animal toxicology studies, when phentolamine was administered orally to pregnant mice and rats during the period of organogenesis, skeletal immaturity and decreased growth was observed in the offspring at doses at least 24-times the recommended clinical dose. Additionally, a lower rate of implantation was seen in pregnant rats treated with phentolamine administered at least 60-times the recommended clinical dose. No malformations or embryofetal deaths were observed in the offspring of pregnant mice, rats, and rabbits administered phentolamine during the period of organogenesis at doses of at least 24-, 60-, and 20-times, respectively, the recommended clinical dose (see Data). RYZUMVI should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus.
There is no information regarding the presence of phentolamine in human milk, the effects on the breastfed infants, or the effects on milk production during lactation to inform risk of phentolamine ophthalmic solution 0.75% to an infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RYZUMVI and any potential adverse effects on the breastfed child from RYZUMVI.
Oral administration of phentolamine to pregnant rats and mice at doses at least 24-times the recommended clinical dose (based on a body weight per surface area (mg/m2) comparison with a 60-kg human) resulted in slightly decreased growth and slight skeletal immaturity of the fetuses. Immaturity was manifested by increased incidence of incomplete or unossified calcanei and phalangeal nuclei of the hind limb and of incompletely ossified sternebrae. At oral phentolamine doses at least 60-times the recommended clinical dose (based on a mg/m2 comparison with a 60-kg human), a slightly lower rate of implantation was found in rats. Phentolamine did not affect embryonic or fetal development in rabbits at oral doses at least 20-times the recommended dose (based on a mg/m2 comparison with a 60-kg human). No malformations or embryofetal deaths were observed in the rat, mouse or rabbit studies.
Presbyopia does not occur in the pediatric population.
Clinical studies of RYZUMVI for the treatment of presbyopia did not include subjects aged 65 and over to determine whether they respond differently from younger subjects. Other clinical experience with RYZUMVI has not identified overall differences in safety between elderly and younger adult subjects.
The safety and effectiveness of RYZUMVI for the treatment of pharmacologically-induced mydriasis have been established in pediatric patients aged 3 to 17 years. No overall differences have been observed between pediatric and adult subjects [see Clinical Studies (14)].
No overall differences in safety and effectiveness have been observed between elderly and younger adult subjects.
No deaths due to acute poisoning with phentolamine have been reported. Overdosage with parenterally administered phentolamine is characterized chiefly by cardiovascular disturbances, such as arrhythmias, tachycardia, hypotension, and possibly shock. In addition, the following might occur: excitation, headache, sweating, visual disturbances, nausea, vomiting, diarrhea, or hypoglycemia. There is no specific antidote; treatment consists of appropriate monitoring and supportive care. Substantial decreases in blood pressure or other evidence of shock-like conditions should be treated vigorously and promptly.
RYZUMVI (phentolamine ophthalmic solution) 0.75% is a sterile, clear and colorless solution for topical ophthalmic use containing 1% phentolamine mesylate (equivalent to 0.75% phentolamine). The product does not contain an anti-microbial preservative. The chemical name of phentolamine mesylate is 3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol; methanesulfonic acid (parent phentolamine: [3-[[(4,5-dihydro-1H-imidazol-2-yl)methyl](4-methylphenyl)amino]phenol]) and the molecular formula is C18H23N3O4S (parent C17H19N3O). The molecular weight of phentolamine mesylate is 377.46 and the chemical structure is:
Chemical Structure (Image 01)
Each mL of RYZUMVI contains phentolamine mesylate 10 mg as the active ingredient (equivalent to 7.5 mg phentolamine as the free base). Inactive ingredients are mannitol, sodium acetate trihydrate, and water for injection. Hydrochloric acid and/or sodium hydroxide are added to adjust pH (4.5 to 5.5), and the solution is overlaid with nitrogen.
RYZUMVI is a relatively non-selective alpha-1 and alpha-2 adrenergic antagonist. Physiological dilation of the pupil is primarily controlled by the radial iris dilator muscles surrounding the pupil; these muscles are activated by the alpha-1 adrenergic receptors. Phentolamine reversibly binds to these receptors on the iris dilator muscle, thereby reducing pupil diameter, with no effect on the ciliary muscle. Phentolamine directly antagonizes the mydriatic effect of an α-1 adrenergic agonist, and indirectly reverses mydriasis induced by muscarinic antagonist effects on the iris sphincter muscle.
The onset of action after administration of RYZUMVI generally occurs in 30 minutes, with the maximal effect seen in 60 to 90 minutes, and the effect lasting at least 24 hours.
Phentolamine systemic exposure was evaluated in a Phase 3 trial (MIRA-3) following topical ocular administration of a total of 3 drops, each of 0.03 mL, of phentolamine ophthalmic solution 0.75%. The peak concentration levels are achieved between 15 minutes and 1 hour after dosing with the median value of 0.45 ng/mL.
Carcinogenicity studies with RYZUMVI have not been conducted.
Phentolamine was not mutagenic in the in vitro bacterial reverse mutation (Ames) assay. In the in vitro chromosomal aberration study in Chinese hamster ovary cells, numerical aberrations were slightly increased after a 4-hour exposure to phentolamine without metabolic activation, and structural aberrations were slightly increased after a 4-hour exposure to phentolamine with metabolic activation only at the highest concentrations tested, but neither numerical nor structural aberrations were increased after a 20-hour exposure without metabolic activation. Phentolamine was not clastogenic in two in vivo mouse micronucleus assays.
The effect of phentolamine on female fertility has not been studied. Male rats treated with oral phentolamine for 9 weeks (4 weeks prior to mating, 3 weeks during the mating period and 2 weeks after mating) were mated with untreated females. At doses up to 648-times human therapeutic exposure levels at the Cmax, no adverse effects on male fertility parameters or on reproductive parameters in the untreated females mated with the treated males were observed.
The efficacy of RYZUMVI for the treatment of presbyopia was demonstrated in two randomized, double-masked, vehicle-controlled Phase 3 trials: VEGA-2 (NCT05646719) and VEGA-3 (NCT06542497). A total of 902 subjects, aged 40 to 64 years, who had binocular distance corrected near visual acuity (DCNVA) of 20/50 to 20/100 and binocular best corrected distance visual acuity (BCDVA) of 20/25 or better were randomized.
Subjects received one drop of RYZUMVI or vehicle in both eyes once daily at night. Subjects with light and dark irides were included in both trials.
At Day 8 (12 hours after seven days of daily dosing), the proportion of study eyes showing an improvement of ≥ 3 lines (15 letters) in DCNVA under photopic conditions, at 40 cm with < 5-letter loss in BCDVA at 4 meters was statistically significantly greater in the RYZUMVI group than in the vehicle group (p < 0.01) across both VEGA-2 and VEGA-3 (see Table 1).
In VEGA-2, at 20 hours post-dose, 24% of RYZUMVI-treated subjects compared to 15% vehicle-treated subjects achieved a ≥3-line improvement in DCNVA.
VEGA-2 | VEGA-3 | |||||
RYZUMVI | Vehicle | p-value | RYZUMVI | Vehicle | p-value | |
Day 1 1 hour after dose 1 | 13.5% | 6.1% | p < 0.05 | 20.6% | 6.1% | p < 0.01 |
Day 8 12 hours after dose 7 | 22.6% | 11.0% | p < 0.01 | 27.2% | 11.5% | p < 0.01 |
The efficacy of RYZUMVI for the reversal of mydriasis was demonstrated in two randomized, double-masked, vehicle-controlled trials; MIRA-2 (NCT04620213) and MIRA-3 (NCT05134974). A total of 553 subjects, aged 12 to 80 years, who had mydriasis induced by instillation of phenylephrine or tropicamide or a combination of hydroxyamphetamine hydrobromide and tropicamide (Paremyd®) were randomized. Subjects with light and dark irides were included in both trials. Two drops (study eye) or one drop (fellow eye) of RYZUMVI or placebo (vehicle) were administered one hour after instillation of the mydriatic agent. The percentage of subjects with study eyes returning to ≤ 0.2 mm from baseline pupil diameter was statistically significantly greater (p < 0.01) at all time points measured from 60 minutes through 24 hours in the RYZUMVI group compared with the placebo (vehicle) group across both of the MIRA-2 and MIRA-3 trials (see Figure 2).
Figure 2. Percentage Of Subjects With Study Eyes Returning To ≤ 0.2 Mm From Baseline Pupil Diameter By Time Point In The Mira-2 And Mira-3 Trials (Image 07)
The efficacy of MIRA-2 and MIRA-3 also showed that the change from maximum pupil dilation in study eyes and fellow eyes was statistically significantly different between the RYZUMVI-treated group and the placebo-treated group at all time points from 60 minutes through 24 hours post-treatment (p < 0.01). Pupil size at 24 hours was 1 mm smaller than baseline. These results were consistent regardless of whether phenylephrine or tropicamide/Paremyd were used as mydriatic agents (Figure 3, Figure 4; respectively).
Figure 3: Pupil Dilation By Time Point With Phenylephrine As Mydriatic Agent In Mira-2 And Mira-3 Trials (mitt Population) (Image 08)
Figure 4: Pupil Dilation By Time Point With Tropicamide Or Paremyd As Mydriatic Agent In Mira-2 And Mira-3 Trials (mitt Population) (Image 09)
The efficacy of RYZUMVI was similar for all age ranges including pediatric subjects aged 3 to 17 years. Pediatric subjects aged 12 to 17 years (n = 27) were treated in MIRA-2 and MIRA-3 and pediatric subjects, aged 3 to 11 years (n = 11) were treated in MIRA-4, (NCT05223478).
RYZUMVI (phentolamine ophthalmic solution) 0.75% is supplied as a sterile, clear, and colorless solution for topical ophthalmic use contained in a translucent, low-density polyethylene, single-dose vial with a 0.2 mL fill. One strip of 5 single-dose vials is packaged into a foil pouch, with 5 or 6 foil pouches in a carton. One single-dose vial can be used to dose both eyes.
Carton of 25 single-dose vials – NDC-83368-075-32
Carton of 30 single-dose vials – NDC-83368-075-30
Storage and Handling:
Store refrigerated at 2°C to 8°C (36°F to 46°F) in original packaging, not to exceed the expiration date printed on the carton and pouch. Protect from freezing.
If the carton or pouch is removed from refrigeration, RYZUMVI may be stored at room temperature [20°C to 25°C (68°F to 77°F)] but must be used within 35 days, not to exceed the expiration date printed on the vial. The vial once opened should be discarded immediately after use. Unused vials should remain in the opened foil pouch until ready for use.
Potential for Eye Injury or Contamination
Advise patients to avoid touching the vial tip to the eye or to any other surface in order to prevent eye injury or contamination [see Warnings and Precautions (5.2)].
Contact Lens Wear
Advise patients to remove contact lenses prior to the instillation of RYZUMVI. Wait 10 minutes after dosing before reinserting contact lenses [see Warnings and Precautions (5.3)].
Concomitant Topical Ocular Therapy
Advise patients if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart [see Dosage and Administration (2.3)].
© 202X Viatris Inc.
RYZUMVI is a registered trademark of Opus Genetics, Inc., licensed to the Viatris Companies.
The brands listed are trademarks of their respective owners.
Distributed by:
Oyster Point Pharma, Inc., a Viatris Company
Morgantown, WV 26505 U.S.A.
OYP:RZMVI:RX5
NDC: 83368-075-32
Rx Only
Ryzumvi®
(phentolamine
ophthalmic solution) 0.75%
FOR TOPICAL USE IN THE EYES
Sterile
Contents: 25 single-dose vials (5 pouches containing
5 single-dose vials each)
Dosage: See Prescribing Information.
Active: Each mL contains phentolamine mesylate 10 mg (equivalent to 7.5 mg phentolamine as the free
base); Inactives: mannitol, sodium acetate trihydrate, and water for injection. May contain either
hydrochloric acid or sodium hydroxide to adjust pH.
Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F) in original packaging, not to exceed the expiration
date printed on the carton and pouch. Protect from freezing. If the carton or pouch is removed from
refrigeration, RYZUMVI may be stored at room temperature [20°C to 25°C (68°F to 77°F)] but must be used within
35 days, not to exceed the expiration date printed on the vial. The vial once opened should be discarded
immediately after use. Unused vials should remain in the opened foil pouch until ready for use. Does not
contain an anti-microbial preservative.
OYP:075:5C:R4
Distributed by:
Oyster Point Pharma, Inc.,
a Viatris Company
Morgantown, WV 26505 U.S.A.
© 2026 Viatris Inc.
RYZUMVI is a registered trademark and
the Ryzumvi Logo is a trademark of Opus
Genetics, Inc., licensed to the Viatris
Companies.
Ryzumvi (phentolamine Ophthalmic Solution) 0.75% Carton Label (Image 03)
* Please review the disclaimer below.
